Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...

I was thinking about a program to solve Sudoku.You fill a 9x9 grid with numbers from 1 to 9. The same number must not be ...

Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial ...

Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...

Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...

Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate ...

Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...

What happens when an AI becomes capable of observing itself, modifying its internal structure, and retraining itself? Using ...

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...